Ultragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($1.84), $0.38 worse than the analyst estimate of ($1.46). Revenue for the quarter came in at $136 million versus the consensus estimate of $160.69 million.

GUIDANCE:

Ultragenyx Pharma sees FY2026 revenue of $730-760 million, versus the consensus of $746.2 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.